Truist Securities Maintains Buy on MBX Biosciences, Raises Price Target to $70
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Truist Securities analyst Srikripa Devarakonda maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $50 to $70.
Truist Securities analyst Srikripa Devarakonda maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $50 to $70.